← Back to all signals
RESEARCH PAPER ANALYSIS

Visuospatial cognition in people with Parkinson's disease: a pilot study assessing a block span task using fMRI.

Pilot fMRI feasibility study demonstrating that people with mild–moderate Parkinson’s can perform a Block Span Task in scanner, which engages expected visuospatial working-memory networks (superior temporal gyrus, superior medial frontal gyrus, precuneus, posterior cingulate).

PMID41959607
JournalFrontiers in human neuroscience
Publication Date2026-01-01
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

Pilot fMRI feasibility study demonstrating that people with mild–moderate Parkinson’s can perform a Block Span Task in scanner, which engages expected visuospatial working-memory networks (superior temporal gyrus, superior medial frontal gyrus, precuneus, posterior cingulate).

WHY IT MATTERS

Research significance

This work has limited direct therapeutic discovery value but is useful as a tool-validation step for assessing visuospatial network dysfunction and may support future biomarker or cognitive-intervention studies if replicated and expanded.

ABSTRACT

Source abstract

BACKGROUND: Impaired visuospatial working memory (WM) often negatively impacts the quality of life of patients with Parkinson's Disease (PD). The Block Span Task (BST) is a novel Corsi-Block-like task adapted for use in functional magnetic resonance imaging (MRI) scanner to understand the neurophysiological mechanisms underlying visuospatial impairment in PD. This pilot study examines whether the BST is a practical tool to provide an in-scanner visuospatial WM task for older adults with mild-moderate PD. METHODS: We recruited and assessed 21 older adults with mild-moderate PD (F = 9, M = 12, age: 70 ± 8 years, Hoehn and Yahr stage: 2.31 ± 0.54), with no overt dementia for participation in the task while lying in the scanner. They abstained from their anti-Parkinsonian medications for 12 h before the assessment. In scanner, participants viewed sequences of block locations on the screen before replicating the sequences on the corresponding buttons of a response pad. Following independent component analysis, components with positive, significant beta values were identified. RESULTS: Administration of the BST task in an older PD population shows feasibility. Results from the encoding phase of the task were aligned with its intended design, implicating recruitment of neural networks with justifiable visuospatial WM involvement. The encoding phase of the task implicated recruitment of the superior temporal gyrus, superior medial frontal gyrus, precuneus, and posterior cingulate cortex, including auditory, cognitive, and default-mode networks. CONCLUSION: This pilot study provides initial evidence that impaired patients with PD can complete the BST fMRI task. Further, the BST appeared to engage significant neural regions that were consistent with an encoding condition in this population. Despite having a small sample size, these preliminary findings support that BST may be useful in future examination of visuo-spatial skills and the underlying brain mechanisms in patients with PD. Future works will be needed to replicate and refine these coarse and preliminary observations, and explore the degree of functional alterations in the recruited networks, when compared to healthy individuals.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic